SNDL Inc.

NASDAQ:SNDL

Drug Manufacturers - Specialty & Generic

Healthcare
$1.34 -1.74%

-$0.03 today

Market cap
$326.64M
Beta
0.91
P/E (TTM)
-47.4
EPS (TTM)
-$0.04
52W Low $1.15High $2.89

Volume 1.00M

Average 2.21M

SNDL Acquisitions (Net)

Cash paid for acquiring businesses, net of cash acquired.

SNDL Inc.NASDAQ: SNDL

Acquisitions (Net) · Q1 FY2026 · quarter ended Mar 2026

Acquisitions (net) turns negative

Q1 FY2026 acquisitions (net) was -CA$2.9M, compared with CA$0 a year earlier. Trailing-twelve-month acquisitions (net) was -CA$5.9M. Over 3 fiscal years it compounded at -72.7% a year.

Context

  • Acquisitions (net) amounted to 0.3% of revenue in FY2025, down 4.0 pp from a year earlier.
  • Acquisitions (net) grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly acquisitions (net) holds near -CA$2.9M or moves back toward the trailing-twelve-month quarterly average of -CA$1.48M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-CA$2.9M+45.0% QoQ
Last fiscal yearDec 2025
-CA$3M-92.4% YoY
LTMMar 2026
-CA$5.9M-85.1% YoY
Acquisitions (Net) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-92.4%——
3-year CAGR-72.7%——
5-year CAGR——
10-year CAGR——

Acquisitions (Net) history

CAD · from the cash flow

Latest · FY2025
(3M) CAD
Year-over-year change
+92.4%

Acquisitions (Net) vs competitors

How SNDL compares with its peers on the latest reported figures

  • Peers report in different currencies, so acquisitions (net) is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -85.1% is the 2nd highest of 3, against a peer median of -50.0%.
  • Acquisitions (net) amounts to 0.6% of revenue for SNDL, versus a peer median of 0.0%.
SNDL Competitors
Acquisitions (Net) for SNDL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SNDLSNDL Inc.LTM Mar 2026CA$5.9M CAD-85.1%-72.7%0.6%
AKBAAkebia Therapeutics, Inc.LTM Mar 2026$172K USD+0.0%—0.1%
CMPSCOMPASS Pathways plcLTM Mar 2026$0 USD———
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$0 USD———
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$0 USD———
ESPREsperion Therapeutics, Inc.LTM Mar 2026$0 USD——0.0%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026$0 USD——0.0%
EOLSEvolus, Inc.LTM Mar 2026$0 USD——0.0%
EBSEmergent BioSolutions Inc.LTM Mar 2026$0 USD-100.0%—0.0%
SIGASIGA Technologies, Inc.LTM Mar 2026$0 USD——0.0%
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding SNDL) —-50.0%—0.0%

Competitors are the stored peer set for SNDL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(230.18M)(372.43M)(176.55M)(96.2M)(15.77M)
Depreciation & Amortization9.6M47.32M64.95M56.71M56.27M
Deferred Income Tax(2.27M)(7.34M)0(9.41M)0
Stock-Based Compensation12.31M9.67M15.4M20.04M13.91M
Change in Working Capital(1.53M)(22.07M)(32.88M)(7.45M)1.43M
Accounts Receivables00000
Inventory16.98M7.01M000
Accounts Payables00000
Other Working Capital(18.51M)(29.09M)(32.88M)(7.45M)1.43M
Other Non-Cash Items56.64M338.14M112.43M91.22M15.08M
Operating Cash Flow(155.44M)(6.71M)(16.65M)54.91M70.92M
Capital Expenditures(3.79M)(10.86M)(7.93M)(11.02M)(12.81M)
Acquisitions (Net)(478.34M)(147.78M)(21.39M)(39.48M)(3M)
Purchases of Investments(24.21M)(75.6M)(732K)0(16.41M)
Sales of Investments10.68M00045.58M
Other Investing Activities(612K)4.07M5.15M65.85M4.1M
Investing Cash Flow(496.28M)(230.16M)(24.82M)17.76M17.45M
Debt Repayment(10.36M)(37.69M)(41.01M)(36.95M)(39.25M)
Common Stock Issued1.06B22K000
Common Stock Repurchased0(13.39M)(1.54M)(13.28M)(15.35M)
Dividends Paid00000
Other Financing Activities97.65M9.27M(531K)871K106K
Financing Cash Flow1.15B(41.79M)(43.08M)(49.36M)(54.49M)
Effect of Forex Changes(9K)0000
Net Change in Cash497.88M(278.67M)(84.55M)23.32M33.88M
Free Cash Flow(159.23M)(17.57M)(24.58M)43.9M58.11M

SNDL Inc.

NASDAQ:SNDL

Intrinsic Alpha fair value

Locked

Current Price

$1.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.